Rotavirus vaccines: Is the second time the charm?

Current Opinion in Investigational Drugs

Volumn 6, Issue 8, 2005, Pages 798-803

  Ward, Richard L ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Efficacy; Immunogenicity; Rotavirus; Safety; Vaccines

Indexed keywords

BOVINE ROTAVIRUS VACCINE; PLACEBO; RIX 4414; ROTAVIRUS VACCINE; SIMIAN ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INTUSSUSCEPTION; LICENSING; NONHUMAN; REVIEW; RNA VIRUS INFECTION; ROTAVIRUS; VACCINATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; DEVELOPING COUNTRIES; HISTORY, 20TH CENTURY; HUMANS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 23344445368     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Adams WR, Kraft LM: Epizootic diarrhea of Infant mice: Identification of the etiologic agent. Science (1963) 141:359-360.
2. Malherbe HH, Harwin R, Ulrich M: The cytopathic effect of vervet monkey viruses. S Afr Med J (1963) 37:407-411.
3. Mebus CA, Underdahl NR, Rhodes MB, Twiehaus MJ: Calf diarrhea (scours): Reproduced with a virus from a field outbreak. Univ Nebraska Res Bull (1969) 233:1-16.
4. Bishop RF, Davidson GP, Holmes IH, Ruck BJ: Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet (1973) 2(7841):1281-1283.
5. GlaxoSmithKline plc: GlaxoSmithKline's global launch with Rotarix starts in Mexico. Press Release (2005): January 07.
6. Wyeth-Lederle Vaccines: Wyeth Lederle Vaccines voluntarily withdraws from the market its rotavirus vaccine RotaShield. Press Release (1999): October 15.
7. Kapikian AZ, Hoshino Y, Chanock RM: Rotaviruses. In: Fields Virology, Fourth Edition. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (Eds), Lippincott, Williams & Wilkins, Philadelphia, PA, USA (2001):1787-1833.
8. Nakagomi O, Nakagomi T: Interspecies transmission of rotaviruses studied from the perspective of genogroup. Microbiol Immunol (1993) 37(5):337-348.
9. Vesikari T: Clinical trials of live oral rotavirus vaccines: The Finnish experience. Vaccine (1993) 11(2):255-261.
10. Vesikari T, Isolauri E, Delem A, D'Hondt E, Andre FE, Zissis G: Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet (1983) 2(8354):807-811.
11. Vesikari T, Isolauri E, Delem A, D'Hondt E Andre FE, Beards GM, Flewett TH: Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr (1985) 107(2):189-194.
12. Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G: Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet (1984) 1(8384):977-981.
13. Hanlon P, Hanlon L, Marsh V, Byass P, Shenton F, Hassan-King M, Jobe O, Sillah H, Hayes R, M'Boge BH, Whittle HC, Greenwood BM: Trial of an attenuated bovine rotavirus vaccine (RIT4237) in Gambian infants. Lancet (1987) 1(8546):1342-1345.
14. Santosham M, Moulton LH, Reid R, Croll J, Weatherholt R, Ward R, Forro J, Zito E, Mack M, Brenneman G, Davidson BL: Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr (1997) 131 (4):632-638.
15. Vesikari T, Ruuska T, Delem A, Andre FE, Beards GM, Flewett TH: Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Pediatr Scand (1991) 80(2):173-180.
16. Clark HF: Rotavirus vaccines. In: Vaccines. Plotkin SA, Mortimer EA (Eds), Saunders, Philadelphia, PA, USA (1988):517-525.
17. Clark HF, Borian EE, Bell LM, Modesto K, Gouvea V, Plotkin SA: Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis (1988) 158(3):570-587.
18. Bernstein DI, Smith VE, Sander DS, Pax KS, Schiff GM, Ward RL: Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis (1990) 162(5):1055-1062.
19. Georges-Courbot MC, Monges J, Siopathis MR, Roungou JB, Gresenguet G, Bellec L, Bouquety JC, Lanckriet C, Cadoz M, Hessel L, Gouvea G et al: Evaluation of the efficacy of a low passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol (1991) 142(5):405-411.
20. Losonsky GA, Rennels MB, Kapikian AZ, Midthun K, Ferra PJ, Fortier DN, Hoffman KM, Baig A, Levine MM: Safety, infectivity, transmissibility, and immunogenicity of rhesus rotavirus vaccine (MMU 18006) in infants. Pediatr Infect Dis (1986) 5(1):25-29.
21. Perez-Schael I, Gonzalez M, Daoud N, Perez M, Soto I, Garcia D, Daoud G, Kapikian AZ, Flores J: Reactogenicity and antigenicity of the rhesus rotavirus vaccine in Venezuelan children. J Infect Dis (1987) 155(2):334-338.
22. Vesikari T, Kapikian AZ, Delem A, Zissis G: A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J infect Dis (1986) 153(5):832-839.
23. Flores J, Perez-Schael I, Gonzalez M, Garcia D, Perez M, Daoud N, Cunto W, Chanock RM, Kapikian AZ: Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet (1987) 1(8538):882-884.
24. Flannels MB, Losonsky GA, Levine MM, Kapikian AZ: Preliminary evaluation of the efficacy of rhesus rotevirus vaccine strain MMU 18006 in young children. Pediatr Infect Dis (1986) 5(5):587-588.
25. Perez-Schael I, Garcia D, Gonzalez M, Gonzalez R, Daoud N, Perez M, Cunto W, Kapikian AZ, Flores J: Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotevirus vaccine. J Med Virol (1990) 30(3):219-229.
26. Rennels MB, Losonsky GA, Young AE, Shindledecker CL, Kapikian AZ, Levine MM: An efficacy trial of the rhesus rotevirus vaccine in Maryland. The Clinical Study Group. Am J Dis Child (1990) 144(5):601-604.
27. Vesikari T, Rautanen T, Varis T, Beards GM, Kapikian AZ: Rhesus rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. Am J Dis Child (1990) 144(3):285-289.
28. Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, Hoshino Y, Kapikian A, Dolin R: Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J (1988) 7(9):645-650.
29. Global Alliance for Vaccines and Immunization (GAVI). GAVI Task Force for R&D Rotavirus Vaccine Agenda Meeting: Minutes and Summary of the Meeting. World Health Organization, Geneva, Switzerland (2001).
30. Vesikari T, Ruuska T, Koivu HP, Green KY, Flores J, Kapikian AZ: Evaluation of the M37 human rotavirus vaccine in 2- to 6-month-old infants. Pediatr Infect Dis J (1991) 10(12):912-917.
31. Flores J, Perez-Schael I, Blanco M, White L, Garcia D, Vilar M, Cunto W, Gonzalez R, Urbina C, Boher J, Mendez M, Kapikian AZ: Comparison of reactogenicity and antigenicity of M37 rotavirus vaccine and rhesus-rotavirus-based quadrivalent vaccine. Lancet (1990) 336(8711):330-334.
32. Flores J, Midthun K, Hoshino, Y, Green K, Gorziglia M, Kapikian AZ, Chanock RM: Conservation of the fourth gene among rotaviruses recovered from asymptomatic newborn infants and its possible role in attenuation. J Virol (1986) 60(3):972-979.
33. Gorziglia M, Hoshino Y, Buckler-White A, Blumentals I, Glass R, Flores J, Kapikian AZ, Chanock RM: Conservation of amino acid sequence of VP8 and cleavage region of 84-kDa outer capsid protein among rotaviruses recovered from asymptomatic neonatal infection. Proc Natl Acad Sci USA (1986) 83(18):7039-7043.
34. Bishop RF, Barnes GL, Cipriani E, Lund JS: Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med (1983) 309(2):72-76.
35. Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI: Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis (1993) 168(2):282-287.
36. Aijaz S, Gowda K, Jagannath HV, Reddy RR, Maiya PP, Ward RL, Greenberg HB, Raju M, Babu A, Rao CD: Epidemiology of symptomatic human rotaviruses in Bangalore and Mysore, India, from 1988 to 1994 as determined by electropherotype, subgroup and serotype analysis. Arch Virol (1996) 141(3-4):715-726.
37. Clark HF, Offit PA, Ellis RW, Eiden JJ, Krah D, Shaw AR, Pichichero M, Treanor JJ, Borian FE, Bell LM, Plotkin SA: The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis (1996) 174(Suppl 1):S73-S80.
38. Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL: Protection from rotavirus reinfection: 2-Year prospective study. J Infect Dis (1991) 164(2):277-283.
39. Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, Spriggs DR, Ward RL: Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: A randomised placebo-controlled trial. Lancet (1999) 354(9175):287-290.
40. Bernstein DI, Ward RL: Rotaviruses. In: Textbook of Pediatric Infectious Diseases, Fifth Edition. Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia, PA, USA (2004):2110-2133.
41. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA: Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. J Am Med Assoc (1995) 273(15):1191-1196.
42. Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, Mack ME, Davidson BL, Kapikian AZ: Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - Report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics (1996) 97(1):7-13.
43. Perez-Schael I, Guntiñas MJ, Perez M, Pagone V, Rojas AM, Gonzalez R, Cunto W, Hoshino Y, Kapikian AZ: Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med (1997) 337(17):1181-1187.
44. Joensuu J, Koskenniemi E, Pang XL, Vesikari T: Randomised placebo-controlled trial of rhesus-human reassortant rotevirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet (1997) 350(9086):1205-1209.
45. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumann AO, Okoro CA, Zanardi LR, Setia S, Fair E, LeBaron CW, Wharton M et al: Intussusception among infants given an oral rotavirus vaccine. N Engl J Med (2001) 344(8):564-572.
46. Glass RI, Bresee JS, Parashar UD, Jiang B, Gentsch J: The future of rotavirus vaccines: A major setback leads to new opportunities. Lancet (2004) 363(9420):1547-1550.
47. Rennels MB, Parashar UD, Holman RC, Le CT, Chang FIG, Glass RI: Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr Infect Dis J (1998) 17(10):924-925.
48. Vesikari T, O'Ryan M, Abate H, Costa Clemens S-A, Espinoza F, Gillard P, Linhares AC, Lopez P, Marcis Parra M, Ortega E, Richardson V et al: Overcoming the safety hurdle: The rotavirus vaccine RIX4414 is not associated with intussusception. Annual Meeting of the European Society for Paediatric Infectious Diseases (2005) 23:Abs 31.
49. Vesikari T, Matson D, Van Damme P, Heyse J, Dallas M, Goveia M, Black S, Shinefield H, Christie C, Rodriguez Z, Boslego J et al: Incidence of intussusception with the pentavalent (human-bovine) reassortant rotavirus vaccine (PRV) is similar to placebo. Annual Meeting of the European Society for Paediatric Infectious Diseases (2005) 23:Abs 46.
50. Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, De Vos B: Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J (2004) 23(10):937-943.
51. De Vos B, Vesikari T, Linhares AC, Salinas B, Perez-Schael I, Ruiz-Palacios GM, Guerrero Mde L, Phua KB, Delem A, Hardt K: A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J (2004) 23(10 Suppl):S179-S182.
52. Velazguez FR, Abate H, Costa Clemens S, Espinoza F, Gillard P, Linhares AC, Lopez P, Marcis Parra M, O'Ryan M, Ortega E, Pavia N et al: The monovalent G1P[8] rotavirus vaccine Rotarix, is highly efficacious and provides cross-protection against G1 and non-G1 serotypes. Annual Meeting of the European Society for Paediatric Infectious Diseases (2005) 23:Abs 51.
53. Vesikari T, Matson D, Dennehy P, Santosham M, Rodriguez Z, Goveia M, Dallas M, Adeyi B, Boslego J, Heyse J, Miller J et al: Protection against rotavirus gastroenteritis of multiple serotypes by a pentavalent (human-bovine) reassortant rotavirus vaccine (PRV). Annual Meeting of the European Society for Paediatric Infectious Diseases (2005) 23:Abs 32.
54. O'Neal CM, Crawford SE, Estes MK, Conner ME: Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol (1997) 71(11):8707-8717.
55. Choi AH-C, Basu M, McNeal MM, Clements JD, Ward RL: Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J Virol (1999) 73(9):7574-7581.